Benzamide derivatives and uses thereof
By developing new benzamide compounds, the problem of poor pharmacokinetic properties of existing sEH inhibitors has been solved, effective inhibition of sEH is achieved, and the therapeutic effect of related diseases has been significantly improved. It is used to treat various inflammatory diseases. and metabolic diseases.
Patent Information
- Application Number
- CN202111318201.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-11-09
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing soluble epoxide hydrolase (sEH) inhibitors have insufficient pharmacokinetic properties, resulting in poor effectiveness in treating diseases such as inflammation and no drug approval is available for the market.
A series of novel benzamide compounds and their pharmaceutically acceptable salts, solvates or prodrugs, as well as pharmaceutical compositions containing these compounds, were developed to inhibit the activity of sEH, and their inhibitory activity was found through in vitro and in vitro inhibitory activity tests. sEH has significant inhibitory activity and stabilizes the levels of EETs in vivo.
These compounds can significantly inhibit carrageenan-induced foot swelling and pain, release of inflammatory factors induced by lipopolysaccharides, protect traumatic brain injury, maintain blood sugar homeostasis, improve diabetic retinopathy, resist tissue fibrosis, relieve depression and other effects. Used to treat sEH-mediated inflammatory diseases, cardiovascular and cerebrovascular diseases, diabetes and complications, fibrotic diseases, neurological and mental diseases, pain, ulcerative diseases, etc.
Smart Images

Figure CN116102525B_ABST
Abstract
Description
Technical field:
[0001] The present invention relates to the field of pharmaceutical chemistry, and in particular to a series of novel benzamide compounds and pharmaceutically acceptable salts, solvates or prodrugs thereof, as well as pharmaceutical compositions containing the compounds and uses thereof. Background technology:
[0002] Epoxide hydrolases (EH) are widely distributed in mammals, insects, plants and microorganisms. At present, epoxide hydrolases are divided into 8 subtypes based on enzyme activity, biochemical characteristics and current research results. Soluble epoxide hydrolases (sEH) are one of the epoxide hydrolases that have been studied more deeply at this stage. In recent years, a large number of studies have shown that soluble epoxide hydrolases are potential therapeutic targets for many diseases such as cardiovascular and cerebrovascular diseases, fibrotic diseases, diabetes, neurological and psychiatric diseases, pain, ulcerative diseases, inflammation and other immune system diseases.
[0003] Human soluble epoxide hydrolase (HsEH) is encoded by the EPHX2 gene located in the P21-P12 region of chromosome 8 and is a member of the α / β hydrolase family. At the same time, studies have found that HsEH is a homodimer composed of two 60kD subunits in an antiparallel manner, each of which has the characteristics of a C-terminal hydrolase and an N-terminal phosphatase. The C-terminal domain has typical α / β hydrolase characteristics. The N-terminal domain has phosphatase activity and can hydrolyze lipid phosphates, but its specific biological function in the human body is still unclear.
[0004] In the human body, sEH is expressed in almost all organs, including the liver, kidney, lung, heart, brain, spleen, adrenal gland, intestine, bladder, vascular endothelium and smooth muscle. sEH plays an important role in lipid epoxide metabolism. Its endogenous substrates include epoxyeicosatrienoic acids (EETs). EETs are a class of endogenous chemical mediators with multiple physiological functions, including angiogenesis, cell apoptosis, fibrinolysis, mitosis, hormone secretion, vasodilation, bronchial dilation and anti-inflammatory effects. Studies have found that EETs in the body can be rapidly hydrolyzed into dihydroxyeicosatrienoc acids (DHETs) by the action of sEH, thereby losing their activity. Therefore, how to inhibit the activity of sEH has become a key issue. In recent years, studies have shown that the activity of sEH can be reduced by small molecule inhibitors or gene knockout technology to stabilize or increase the content of EETs.
[0005] The pharmacological effects obtained by inhibiting sEH can be measured by the level of intracellular EETs. Research on sEH inhibitors mainly focuses on the effects on blood vessels and inflammation. EETs are activators that inhibit nuclear transcription factor (NFκB). In animal model experiments with inflammation, inhibiting sEH can improve and control the disease. In animal inflammation models, respiratory inflammation caused by tobacco smoke and pulmonary hypertension induced by monocrotaline can be reduced in severity by inhibiting sEH. The anti-inflammatory effect of sEH inhibitors also has a certain effect on cisplatin-induced nephropathy. sEH inhibitors also have a certain analgesic effect, and it is inferred that they may reduce the expression of pain-causing substances. In animal model experiments of cerebral ischemia, inhibiting sEH activity can inhibit ischemic inflammatory responses, stimulate apoptosis of anti-neuronal gene expression, and reduce the effect of cerebral infarction.
[0006] Studies have found that there is a key aspartic acid residue in the catalytic site of sEH, so the early research on sEH inhibitors mainly focused on carboxyl modification reagents. Dicyclohexylcarbodiimide (DCC), as a common reagent in amide bonds and peptide synthesis, can react with carboxylic acids to form corresponding esters. So people unexpectedly found that DCC has good inhibitory activity against sEH. However, according to pharmacokinetic analysis, DCC will hydrolyze into the corresponding urea in solution, which is the main active substance that inhibits sEH, so most of the early sEH inhibitors contain urea structures. At present, there are also some compounds with outstanding activity and good therapeutic effects that are in the preclinical and clinical research stages, such as AR9281, GSK2256294 and EC5026. EC5026 is a urea sEH inhibitor developed by Bruce Hammock's team at the University of California. The drug has completed Phase Ia clinical trials and is indicated for neuropathic pain.
[0007]
[0008] sEH inhibitors have great potential in the treatment of diseases such as inflammation, but due to factors such as poor pharmacokinetic properties of sEH inhibitors, no drugs have been approved for marketing. Therefore, the development of sEH inhibitors with novel structures, high activity, and good pharmacokinetic properties is of great research significance. Summary of the invention:
[0009] The present invention aims to provide a series of novel benzamide compounds and pharmaceutically acceptable salts, solvates or prodrugs thereof, as well as pharmaceutical compositions containing the compounds and uses thereof.
[0010] To achieve the above purpose, the present invention adopts the following technical solution:
[0011] A benzamide derivative, wherein the benzamide derivative is a compound of formula I and its stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs,
[0012]
[0013] in,
[0014] (R 1 ) q is hydrogen, hydroxyl, halogen, cyano, nitro, hydroxyl-substituted (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6) alkoxy; q=a positive integer of 1-4, and when q is greater than 1, R 1 Can be the same or different;
[0015] R 2 For-CONR 5 R 6 , -COCH2NR 5 R 6 、-CH2CONR 5 R 6 ;
[0016] Among them, R 5 and R 6 are the same or different, each independently selected from hydrogen, unsubstituted or substituted with 1-3 identical or different R 7 substituted (C1-C6) alkyl, adamantyl, (C3-C7) cycloalkyl, (C1-C6) alkylacyl, (C2-C6) alkenyl, (C2-C6) alkynyl, 6-10 membered aryl, 5-10 membered heteroaryl, 6-10 membered aryl (C1-C4) alkyl, 5-10 membered heteroaryl (C1-C4) alkyl, and R 5 and R 6 are not hydrogen at the same time; the heteroaryl group contains at least one heteroatom;
[0017] or, R 5 and R 6 Together with the nitrogen atom to which they are attached, they are unsubstituted or substituted with 1-3 identical or different R 7 A substituted 4-10 membered heterocyclic group or 5-10 membered heteroaryl group; the heterocyclic group or heteroaryl group further contains 0-4 heteroatoms selected from N, O or S, and the heterocyclic group further optionally includes 0-2 carbon-carbon double bonds or carbon-carbon triple bonds or is optionally substituted with one or more oxo groups;
[0018] R 7is halogen, nitro, cyano, azido, mercapto, (C1-C6)alkylthio, (C1-C6)alkenyl, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylacyl, (C1-C3)alkylenedioxy, (C1-C6)alkylamido, (C1-C6)alkyl or (C1-C6)alkoxy which are unsubstituted or substituted by at least one hydroxyl, amino or halo group, amino which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups, hydroxyl, free, salified, esterified or amidated carboxyl, or carbamoyl which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups;
[0019] R 3 -(CH2) m NR 8 R 9 、-(CH2) m NHCOR 8 、-(CH2) m OR 8 、-(CH2) m CONR 8 R 9 ;
[0020] m is an integer between 1 and 4;
[0021] R 8 and R 9 are the same or different and are independently selected from hydrogen, (C1-C6) alkyl, (C3-C7) cycloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, unsubstituted or substituted with 1-3 identical or different R 10 A substituted 6-10 membered aryl or 5-10 membered heteroaryl group; wherein the heteroaryl group contains at least one heteroatom;
[0022] or R 8 and R 9 Together with the nitrogen atom to which they are attached, they are unsubstituted or substituted with 1-3 identical or different R 10 A substituted 4-10 membered heterocyclic group or 5-10 membered heteroaryl group, wherein the heterocyclic group or heteroaryl group further contains 0-4 heteroatoms selected from N, O or S, and the heterocyclic group further optionally contains 0-2 carbon-carbon double bonds or carbon-carbon triple bonds or is optionally substituted with one or more oxo groups;
[0023] R 10 is hydroxy, amino, halogen, carboxyl, cyano, nitro, (C1-C6) alkyl, (C1-C6) alkoxy, (C3-C7) cycloalkyl;
[0024] R 4 -CO(CH2) n NR11 R 12 、-(CH2) n CONR 11 R 12 、-SO2NR 11 R 12 、-NH(CH2) n CONR 11 R 12 、-NHCO(CH2) n NR 11 R 12 、-NHCOR 11 ;
[0025] n is 0 or 1;
[0026] Among them, R 11 and R 12 are the same or different and are independently selected from hydrogen, adamantyl, (C3-C7) cycloalkyl, (C1-C6) alkylacyl, (C2-C6) alkenyl, (C2-C6) alkynyl, unsubstituted or substituted with 1-3 identical or different R 13 Substituted (C1-C6) alkyl, 6-10 membered aryl, 5-10 membered heteroaryl, 6-10 membered aryl (C1-C4) alkyl, 5-10 membered heteroaryl (C1-C4) alkyl; the heteroaryl contains at least one heteroatom;
[0027] or R 11 and R 12 Together with the nitrogen atom to which they are attached, they are unsubstituted or substituted with 1-3 identical or different R 13 A substituted 4-10 membered heterocyclic group or 5-10 membered heteroaryl group, wherein the heterocyclic group or heteroaryl group further contains 0-4 heteroatoms selected from N, O or S, and the heterocyclic group further optionally includes 0-2 carbon-carbon double bonds or carbon-carbon triple bonds or is optionally substituted with one or more oxo groups;
[0028] R 13 It is halogen, nitro, cyano, azido, mercapto, (C1-C6)alkylthio, (C1-C6)alkenyl, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylacyl, (C1-C3)alkylenedioxy, (C1-C6)alkylamido, (C1-C6)alkyl or (C1-C6)alkoxy which are unsubstituted or substituted by at least one hydroxyl, amino or halo, amino which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups, hydroxyl, free, salified, esterified or amidated carboxyl, or carbamoyl which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups.
[0029] Preferably, the compound of formula I and its stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs thereof,
[0030] in,
[0031] (R 1 ) q is hydrogen, hydroxyl, halogen, cyano, nitro, hydroxyl-substituted (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6) alkoxy; q=a positive integer of 1-4, and when q is greater than 1, R 1 Can be the same or different;
[0032] R 2 For-CONR 5 R 6 , -COCH2NR 5 R 6 、-CH2CONR 5 R 6 ;
[0033] R 5 and R 6 are the same or different, each independently selected from hydrogen, unsubstituted or substituted with 1-3 identical or different R 7 substituted (C1-C4) alkyl, adamantyl, (C3-C5) cycloalkyl, phenyl, 5-6 membered heteroaryl, phenyl (C1-C3) alkyl, 5-6 membered heteroaryl (C1-C3) alkyl, and R 5 and R 6 are not hydrogen at the same time; the heteroaryl group contains at least one heteroatom;
[0034] or, R 5 and R 6 Together with the nitrogen atom to which they are attached, they are unsubstituted or substituted with 1-3 identical or different R 7 A substituted 5-6 membered heterocyclic group or 5-6 membered heteroaryl group; the heterocyclic group or heteroaryl group further contains 0-4 heteroatoms selected from N, O or S, and the heterocyclic group further optionally includes 0-2 carbon-carbon double bonds or carbon-carbon triple bonds or is optionally substituted with one or more oxo groups;
[0035] R 7is halogen, nitro, cyano, azido, mercapto, (C1-C6)alkylthio, (C1-C6)alkenyl, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylacyl, (C1-C3)alkylenedioxy, (C1-C6)alkylamido, (C1-C6)alkyl or (C1-C6)alkoxy which are unsubstituted or substituted by at least one hydroxyl, amino or halo group, amino which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups, hydroxyl, free, salified, esterified or amidated carboxyl, or carbamoyl which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups;
[0036] R 3 -(CH2) m NR 8 R 9 、-(CH2) m NHCOR 8 、-(CH2) m OR 8 、-(CH2) m CONR 8 R 9 ;
[0037] m is 1-4;
[0038] R 8 and R 9 are the same or different and are independently selected from hydrogen, (C1-C4) alkyl, (C3-C6) cycloalkyl,
[0039] or, R 8 and R 9 Together with the nitrogen atom to which they are attached, they are unsubstituted or substituted with 1-3 identical or different R 10 A substituted 5-6 membered heterocyclic group or 5-6 membered heteroaryl group, wherein the heterocyclic group or heteroaryl group further contains 0-4 heteroatoms selected from N, O or S, and the heterocyclic group further optionally includes 0-2 carbon-carbon double bonds or carbon-carbon triple bonds or is optionally substituted with one or more oxo groups;
[0040] R 10 is hydroxy, amino, halogen, carboxyl, cyano, nitro, (C1-C6) alkyl, (C1-C6) alkoxy, (C3-C7) cycloalkyl;
[0041] R 4 -CO(CH2) n NR 11 R 12 、-(CH2) n CONR 11 R 12 、-NH(CH2)n CONR 11 R 12 、-NHCO(CH2) n NR 11 R 12 、-NHCOR 11 ,
[0042] n is 0 or 1;
[0043] Among them, R 11 and R 12 are the same or different and are independently selected from hydrogen, adamantyl, (C3-C6) cycloalkyl, unsubstituted or substituted with 1-3 identical or different R 13 substituted (C1-C6) alkyl, phenyl, 5-6 membered heteroaryl, phenyl (C1-C3) alkyl, 5-6 membered heteroaryl (C1-C3) alkyl, and R 11 and R 12 are not hydrogen at the same time; the heteroaryl group contains at least one heteroatom;
[0044] or R 11 and R 12 Together with the nitrogen atom to which they are attached, they are unsubstituted or substituted with 1-3 identical or different R 13 A substituted 5-6 membered heterocyclic group or 5-6 membered heteroaryl group, wherein the heterocyclic group or heteroaryl group further contains 0-4 heteroatoms selected from N, O or S, and the heterocyclic group further optionally includes 0-2 carbon-carbon double bonds or carbon-carbon triple bonds or is optionally substituted with one or more oxo groups;
[0045] R 13 It is halogen, nitro, cyano, azido, mercapto, (C1-C6)alkylthio, (C1-C6)alkenyl, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylacyl, (C1-C3)alkylenedioxy, (C1-C6)alkylamido, (C1-C6)alkyl or (C1-C6)alkoxy which are unsubstituted or substituted by at least one hydroxyl, amino or halo, amino which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups, hydroxyl, free, salified, esterified or amidated carboxyl, or carbamoyl which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups.
[0046] Preferably, the compound of formula I and its pharmaceutically acceptable salt, solvate or prodrug thereof,
[0047] in,
[0048] (R 1 ) qis hydrogen, hydroxyl, halogen, methyl, ethyl, methoxy, ethoxy; q=a positive integer from 1 to 4, and when q is greater than 1, R 1 Can be the same or different;
[0049] R 2 For-CONHR 6 ,-COCH2NHR 6 、-CH2CONHR 6 ;
[0050] Among them, R 6 Selected from (C1-C4) alkyl, adamantyl, (C3-C6) cycloalkyl, unsubstituted or substituted with 1-3 identical or different R 7 substituted phenyl, 5-6 membered heteroaryl, phenyl(C1-C2)alkyl, 5-6 membered heteroaryl(C1-C2)alkyl, wherein the phenyl or heteroaryl is optionally substituted by 1-3 identical or different R 7 replace;
[0051] R 7 is halogen, nitro, cyano, azido, mercapto, (C1-C6)alkylthio, (C1-C6)alkenyl, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylacyl, (C1-C3)alkylenedioxy, (C1-C6)alkylamido, (C1-C6)alkyl or (C1-C6)alkoxy which are unsubstituted or substituted by at least one hydroxyl, amino or halo group, amino which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups, hydroxyl, free, salified, esterified or amidated carboxyl, or carbamoyl which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups;
[0052] R 3 -(CH2) m NR 8 R 9 、-(CH2) m OR 8 、-(CH2) m CONR 8 R 9 ;
[0053] m is 1-4;
[0054] R 8 and R 9 are the same or different and are independently selected from hydrogen, (C1-C4) alkyl, (C3-C6) cycloalkyl,
[0055] or, R 8 and R 9Together with the nitrogen atom to which they are attached, they are unsubstituted or substituted with 1-3 identical or different R 10 A substituted 5-6 membered heterocyclic group or 5-6 membered heteroaryl group, wherein the heterocyclic group or heteroaryl group further contains 0-4 heteroatoms selected from N, O or S, and the heterocyclic group further optionally includes 0-2 carbon-carbon double bonds or carbon-carbon triple bonds or is optionally substituted with one or more oxo groups;
[0056] R 10 is hydroxy, amino, halogen, carboxyl, cyano, nitro, (C1-C6) alkyl, (C1-C6) alkoxy, (C3-C7) cycloalkyl;
[0057] R 4 -CO(CH2) n NHR 11 、-(CH2) n CONHR 11 、-NHCO(CH2) n NHR 11 、-NHCOR 11 , n is 0 or 1;
[0058] Among them, R 11 is adamantyl, (C3-C6) cycloalkyl, unsubstituted or substituted with 1-3 identical or different R 13 Substituted (C1-C6) alkyl, phenyl, 5-6 membered heteroaryl, phenyl (C1-C3) alkyl, 5-6 membered heteroaryl (C1-C3) alkyl;
[0059] R 13 It is halogen, nitro, cyano, azido, mercapto, (C1-C6)alkylthio, (C1-C6)alkenyl, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylacyl, (C1-C3)alkylenedioxy, (C1-C6)alkylamido, (C1-C6)alkyl or (C1-C6)alkoxy which are unsubstituted or substituted by at least one hydroxyl, amino or halo, amino which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups, hydroxyl, free, salified, esterified or amidated carboxyl, or carbamoyl which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups.
[0060] Further preferably, in the general formula I, R 2 Select-CONR 5 R 6 , R 5 When is H, the compound is shown in the general formula II,
[0061]
[0062] Where:
[0063] (R 1 ) q is hydrogen, hydroxyl, halogen, methyl, ethyl, methoxy, ethoxy; q=a positive integer from 1 to 4, and when q is greater than 1, R 1 Can be the same or different;
[0064] R 6 Selected from adamantyl, unsubstituted or substituted with 1-3 identical or different R 7 Substituted phenyl, 5-6 membered heteroaryl, phenyl(C1-C2)alkyl, 5-6 membered heteroaryl(C1-C2)alkyl;
[0065] R 7 is halogen, nitro, cyano, azido, mercapto, (C1-C6)alkylthio, (C1-C6)alkenyl, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylacyl, (C1-C3)alkylenedioxy, (C1-C6)alkylamido, (C1-C6)alkyl or (C1-C6)alkoxy which are unsubstituted or substituted by at least one hydroxyl, amino or halo group, amino which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups, hydroxyl, free, salified, esterified or amidated carboxyl, or carbamoyl which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups;
[0066] R 3 -(CH2) m NR 8 R 9 、-(CH2) m CONR 8 R 9 ;
[0067] m is 1-4;
[0068] R 8 and R 9 are the same or different and are independently selected from hydrogen, (C1-C4) alkyl, (C3-C6) cycloalkyl;
[0069] or R 8 and R 9 Together with the nitrogen atoms to which they are attached, they form
[0070] R 4 -CO(CH2) n NHR 11 、-(CH2) n CONHR 11 ;
[0071] n is 0 or 1;
[0072] R 11 is unsubstituted or substituted with 1 to 3 identical or different R 13 Substituted phenyl, 5-6 membered heteroaryl, phenyl (C1-C3) alkyl, 5-6 membered heteroaryl (C1-C3) alkyl, the phenyl and heteroaryl are optionally substituted by 1-3 identical or different R 13 replace;
[0073] R 13 It is halogen, nitro, cyano, azido, mercapto, (C1-C6)alkylthio, (C1-C6)alkenyl, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylacyl, (C1-C3)alkylenedioxy, (C1-C6)alkylamido, (C1-C6)alkyl or (C1-C6)alkoxy which are unsubstituted or substituted by at least one hydroxyl, amino or halo, amino which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups, hydroxyl, free, salified, esterified or amidated carboxyl, or carbamoyl which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups.
[0074] In further preferred embodiments, in the general formula I, R 2 Select-CONR 5 R 6 , R 5 H, R 1 Located at position 3, R 4 Select-CONHR 11 When the compound is shown in the general formula III,
[0075]
[0076] Where:
[0077] R 1 is hydrogen, fluorine, chlorine, bromine, methyl, ethyl, methoxy;
[0078] R 6 is adamantyl, unsubstituted or substituted with 1-3 identical or different R 7 Substituted phenyl, 5-6 membered heteroaryl;
[0079] R 7is halogen, nitro, cyano, azido, mercapto, (C1-C6)alkylthio, (C1-C6)alkenyl, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylacyl, (C1-C3)alkylenedioxy, (C1-C6)alkylamido, (C1-C6)alkyl or (C1-C6)alkoxy which are unsubstituted or substituted by at least one hydroxyl, amino or halo group, amino which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups, hydroxyl, free, salified, esterified or amidated carboxyl, or carbamoyl which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups;
[0080] R 3 -(CH2) m NR 8 R 9 ;
[0081] m is 1-4;
[0082] R 8 and R 9 are the same or different and are independently selected from hydrogen, (C1-C4) alkyl, (C3-C6) cycloalkyl;
[0083] or R 8 and R 9 Together with the nitrogen atoms to which they are attached, they form
[0084] R 11 is unsubstituted or substituted with 1 to 3 identical or different R 13 Substituted phenyl, 5-6 membered heteroaryl;
[0085] R 13 It is halogen, nitro, cyano, azido, mercapto, (C1-C6)alkylthio, (C1-C6)alkenyl, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylacyl, (C1-C3)alkylenedioxy, (C1-C6)alkylamido, (C1-C6)alkyl or (C1-C6)alkoxy which are unsubstituted or substituted by at least one hydroxyl, amino or halo, amino which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups, hydroxyl, free, salified, esterified or amidated carboxyl, or carbamoyl which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups.
[0086] More preferably, the compound of formula III, wherein
[0087] R 1 is hydrogen, fluorine, chlorine, methyl;
[0088] R 3 -(CH2)2NR 8 R 9 ;
[0089] R 8 and R 9 Together with the nitrogen atoms to which they are attached, they form
[0090] R 11 is unsubstituted or substituted with 1 to 3 identical or different R 13 Substituted phenyl groups;
[0091] R 13 It is halogen, nitro, cyano, azido, mercapto, (C1-C6)alkylthio, (C1-C6)alkenyl, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylacyl, (C1-C3)alkylenedioxy, (C1-C6)alkylamido, (C1-C6)alkyl or (C1-C6)alkoxy which are unsubstituted or substituted by at least one hydroxyl, amino or halo, amino which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups, hydroxyl, free, salified, esterified or amidated carboxyl, or carbamoyl which are unsubstituted or substituted by 1-2 identical or different (C1-C6 alkyl) groups.
[0092] The compound of the general formula I of the present invention may be:
[0093] N-(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido]benzamide
[0094] 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-[4-(trifluoromethoxy)phenyl]benzamide
[0095] 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-methoxyphenyl)benzamide
[0096] 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-[4-(trifluoromethyl)phenyl]benzamide
[0097] 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-fluorophenyl)benzamide
[0098] 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(p-tolyl)benzamide
[0099] 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-isopropylphenyl)benzamide
[0100] N-(2-Chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide
[0101] N-(3-Chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide
[0102] N-(3-Chloro-4-fluorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide
[0103] 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-phenylbenzamide
[0104] N-(4-Chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzenesulfonamide
[0105] N-(4-Chlorobenzyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide
[0106] 2-(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)-N-[4-(trifluoromethoxy)phenyl]acetamide
[0107] N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-2-fluorobenzamide
[0108] 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-2-fluoro-N-[4-(trifluoromethoxy)phenyl]benzamide
[0109] N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-fluorobenzamide
[0110] N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-2-methylbenzamide
[0111] N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methylbenzamide
[0112] N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methoxybenzamide
[0113] N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-chlorobenzamide
[0114] 2-[(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)amino]-N-cyclopropylacetamide
[0115] 4-{3-Benzyl-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-chlorophenyl)-3-methylbenzamide
[0116] N-(4-Chlorophenyl)-3-methyl-4-{1-[2-(4-morpholinyl)ethyl]-3-phenylethylureido}benzamide
[0117] N-(4-Chlorophenyl)-4-{3-(4-methoxyphenethyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methylbenzamide
[0118] N-(4-Chlorophenyl)-4-{3-(3-methoxyphenethyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methylbenzamide
[0119] N-(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-(2-methoxyethyl)ureido]-3-methylbenzamide
[0120] Preparation of N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]ureido}-3-methylbenzamide
[0121] N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(diethylamino)ethyl]ureido}-3-methylbenzamide
[0122] N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(pyrrolidin-1-yl)ethyl]ureido}-3-methylbenzamide
[0123] N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(piperidin-1-yl)ethyl]ureido}-3-methylbenzamide
[0124] N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-methylpiperidin-1-yl)ethyl]ureido}-3-methylbenzamide
[0125] N-(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-(2-thiomorpholinoethyl)ureido]-3-methylbenzamide
[0126] N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(1-oxidothiomorpholino)ethyl]ureido}-3-methylbenzamide
[0127] N-(4-Chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(1,1-dioxythiomorpholino)ethyl]ureido}-3-methylbenzamide
[0128] N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(3-oxomorpholino)ethyl]ureido}-3-methylbenzamide
[0129] 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(5-fluoropyridin-2-yl)-3-methylbenzamide
[0130] The salt formed by the compound of the general formula I and an acid, wherein the acid is selected from: hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, trifluoroacetic acid or aspartic acid.
[0131] The present invention also includes prodrugs of the derivatives of the present invention. Prodrugs of the derivatives of the present invention are derivatives of general formula (I) which may themselves have weak activity or even no activity, but after administration, are converted into the corresponding biologically active form under physiological conditions (e.g., by metabolism, solvolysis or other means).
[0132] Unless otherwise indicated, the term "halogen" used in the present invention refers to fluorine, chlorine or bromine; "alkyl" refers to straight-chain or branched alkyl; "cycloalkyl" refers to substituted or unsubstituted cycloalkyl; "alkoxy" refers to straight-chain or branched alkoxy; "alkenyl" refers to straight-chain or branched alkenyl; "alkynyl" refers to straight-chain or branched alkynyl; "aryl" refers to phenyl with no or substituted substituents; "heteroaryl" refers to a monocyclic or polycyclic cyclic group containing one or more heteroatoms selected from N, O, and S. The term "saturated or partially saturated heterocyclic group" refers to a monocyclic or polycyclic ring system containing one or more heteroatoms selected from N, O, and S, such as pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, pyrazolidinyl, imidazolidinyl, and thiazolinyl.
[0133] The present invention also includes a pharmaceutical composition comprising a compound of formula I and their pharmaceutically acceptable salts and / or solvates as an active ingredient and a pharmaceutically acceptable carrier; the compounds of the present invention may be used in combination with other active ingredients as long as they do not produce other adverse effects, such as allergic reactions.
[0134] The carriers used in the pharmaceutical composition of the present invention are common types available in the pharmaceutical field, including: binders, lubricants, disintegrants, solubilizers, diluents, stabilizers, suspending agents, pigments, flavoring agents, etc. for oral preparations; pH regulators, osmotic pressure regulators, solubilizers, stabilizers, etc. for injectable preparations; bases, diluents, lubricants, preservatives, etc. for local preparations. Pharmaceutical preparations can be administered orally, parenterally (e.g., intravenously, subcutaneously, intraperitoneally, etc.) or topically (e.g., ocular, nasal, sublingual, skin, etc.). If some drugs are unstable under gastric conditions, they can be formulated into enteric-coated tablets.
[0135] Through in vitro and in vivo inhibitory activity tests, it was found that the compounds of the present invention have significant inhibitory activity against sEH and stabilize the level of EETs in the body. The results of pharmacodynamic studies show that the compounds of the present invention can inhibit carrageenan-induced foot swelling and pain, as well as lipopolysaccharide-induced inflammatory factor release, protect traumatic brain injury, maintain blood sugar homeostasis, improve diabetic retinopathy, resist tissue fibrosis, relieve depression, etc., and can be used to treat sEH-mediated inflammatory diseases, cardiovascular and cerebrovascular diseases, diabetes and complications, fibrotic diseases, neurological and mental diseases, pain, ulcerative diseases, etc.
[0136] The exact amount of a compound of the invention required to treat a condition mediated by sEH will vary from subject to subject, depending on the species, age and general condition of the subject, the severity of the disease being treated, the specific compound used and the mode of administration, such as route and frequency of administration, etc. An appropriate effective amount can be determined by one of ordinary skill in the art using only routine experimentation.
[0137] The dosage of the compound can be from about 0.1 to 100 mg / kg body weight / day, preferably 1 to 50 mg / kg body weight / day. It is understood that the dosage can vary depending on the patient's needs, the severity of the hypertensive disease, cardiovascular disease, inflammatory disease and diabetes-related disease being treated, and the specific compound used. Moreover, it is understood that the initial dose administered can be increased beyond the upper limit in order to quickly reach the desired blood level, or the initial dose can be less than the optimal value, and the daily dose can be gradually increased during treatment, depending on the specific situation. If necessary, the daily dose can also be divided into multiple doses, such as 2-4 times a day.
[0138] Mammal means a human or an animal.
[0139] The amount of active ingredient, i.e. the compound according to the invention, in the pharmaceutical composition and its unit dosage form may vary, depending on the specific application, the efficacy of the specific compound and the desired concentration. Generally speaking, the content of the active ingredient will be between 0.5% and 90%, based on the total weight of the composition.
[0140] In combination therapy, the compound of the present invention and other compounds may be administered simultaneously or separately. When administered simultaneously, the compound of the present invention and other compounds may be combined in a single pharmaceutical composition or in separate compositions.
[0141] A pharmaceutical composition comprising a compound of general formula I and one or more of its stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs and a pharmaceutically acceptable carrier.
[0142] Use of a compound of general formula I and its stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs or compositions in the preparation of drugs for treating and / or preventing sEH-mediated diseases.
[0143] The diseases include inflammatory diseases, cardiovascular and cerebrovascular diseases, diabetes, diabetic complications, diabetes-related diseases, fibrotic diseases, neurological and psychiatric diseases, pain or ulcerative diseases.
[0144] The examples and preparations provided below further illustrate and illustrate the compounds of the present invention and their preparation methods. It should be understood that the scope of the following examples and preparations does not limit the scope of the present invention in any way.
[0145] The following synthetic routes A, B, C, D, E describe the preparation of the general formula I of the present invention, and all raw materials are prepared by the methods described in these synthetic routes, by methods well known to those of ordinary skill in the field of organic chemistry, or are commercially available. All final compounds of the present invention are prepared by the methods described in these synthetic routes or by methods similar thereto, which are well known to those of ordinary skill in the field of organic chemistry. All variable factors used in these synthetic routes are as defined below or as defined in the claims.
[0146] According to the compound of general formula I of the present invention, in route A, route B, route C, route D and route E, the following compound is taken as an example: R 1 , R 5 , R 8 and R 12 The definition is the same as that in the claims.
[0147]
[0148] Route A Synthesis of Compound Ii
[0149] When R 4 For-CONR 11 R 12 ; R 11 For H, R 12 For different R 13 Substituted phenyl; Substituent R 1 , R 2 and R 3 The definition is the same as that of the claims. The synthetic method for preparing the compound of formula I is route A to obtain compound Ii. The synthetic route further comprises R 1 is hydrogen; R 3 for R 2 for For example, specifically: R 1 Substituted p-nitrobenzoic acid is used as the starting material, and an intermediate D is obtained through acylation reaction, reduction reaction and nucleophilic substitution reaction. p-Chloroaniline and phenyl chloroformate are subjected to substitution reaction to obtain intermediate E. Intermediate D and intermediate E are subjected to urea-forming reaction to obtain compound Ii of general formula I.
[0150]
[0151] Route B Synthesis of Compound I-ii and Compound I-iii
[0152] When R 4 -NHCH2COR 11 R 12 、-NHCOCH2R 11 R 12 ; R 11 For H, R 12 is (C1-C6) alkyl, adamantyl, (C3-C6) cycloalkyl, phenyl, 5-6 membered heteroaryl, phenyl (C1-C3) alkyl, 5-6 membered heteroaryl (C1-C3) alkyl; the substituent R 1 , R 2 and R 3 The definition is the same as that of the claims. The synthetic method for preparing the compound of formula I is route B, and compounds I-ii and I-iii are obtained. The synthetic route is further treated with R 1 is hydrogen; R 3 for R 2 for For example, the specific process is as follows: using p-nitroaniline as the starting material, intermediate K is obtained through Boc protection, reduction reaction, nucleophilic substitution reaction, urea formation reaction and Boc removal reaction. Intermediate K reacts with chloroacetyl chloride and R 12Substituted amines are prepared in one pot to obtain compounds of formula I-ii; or with R 12 The substituted chloroacetamide undergoes a nucleophilic substitution reaction to prepare compound I-iii of the general formula I.
[0153]
[0154] Synthesis of Route C Compound I-iv
[0155] R 2 -COCH2NHR 5 , R 5 is (C1-C4) alkyl, adamantyl, (C3-C6) cycloalkyl, phenyl, 5-6 membered heteroaryl, phenyl (C1-C2) alkyl, 5-6 membered heteroaryl (C1-C2) alkyl, wherein the phenyl or heteroaryl is replaced by different R 7 Substitution; Substituent R 1 , R 3 and R 4 The definition is the same as that of the claims. The synthetic method for preparing the compound of formula I is route C to obtain compound I-iv. The synthetic route further comprises R 1 is a methyl group substituted at the 3-position; R 3 for R 4 for For example, using 3-methyl-4-nitrobenzoic acid as the starting material, compound I-iv of general formula I is prepared through acylation reaction, reduction reaction, nucleophilic substitution reaction, acylation reaction and nucleophilic substitution reaction.
[0156]
[0157] Route D Synthesis of Compound Iv
[0158] When R 2 For-CONR 5 R 6 , R 5 For H, R 6 is (C1-C4) alkyl, adamantyl, (C3-C5) cycloalkyl, phenyl, 5-6 membered heteroaryl, phenyl (C1-C3) alkyl, 5-6 membered heteroaryl (C1-C3) alkyl, wherein the alkyl, aryl and heteroaryl are separated by different R 7 Substitution; Substituent R 1 , R 3 and R 4 The definition is the same as that of the claims. The synthetic method for preparing the compound of formula I is route D to obtain compound Iv. The synthetic route further comprises R 1 is a methyl group substituted at the 3-position; R 3 for R 4 for For example, R 5 The substituted amine reacts with phenyl chloroformate to obtain intermediate Q, which is then reacted with intermediate O to form a urea to obtain compound Iv of general formula I.
[0159]
[0160] Synthesis of compound I-vi in Route E
[0161] When R 3 -(CH2)2NR 8 R 9 , R 8 and R 9 are the same or different and are independently selected from hydrogen, (C1-C4) alkyl, (C3-C6) cycloalkyl, or R 8 and R 9 Together with the nitrogen atoms to which they are attached, they form Substituent R 1 , R 2 and R 4 The definition is the same as that of the claims. The synthetic method for preparing the compound of formula I is route E to obtain compound I-vi. The synthetic route further comprises R 1 is a methyl group substituted at the 3-position; R 2 for R 4 for For example, the synthesis method is to use R 8 The substituted amine is used as the starting material, and is subjected to a substitution reaction with 1-bromo-2-chloroethane to obtain an intermediate R, which is then subjected to a nucleophilic substitution reaction and a urea-forming reaction with an intermediate N to obtain a compound of formula I, I-vi.
[0162] The advantages of the present invention are:
[0163] The compounds of the present invention are different from conventional linear structural types and are trident-like structures, belonging to novel structural benzamide derivatives. At the same time, the compounds are used in the preparation of drugs for treating and / or preventing sEH-mediated diseases, especially in the preparation of drugs for treating inflammatory diseases, cardiovascular and cerebrovascular diseases, diabetes, diabetic complications, diabetes-related diseases, fibrotic diseases, neurological and mental diseases, pain, ulcerative diseases, etc. Description of the drawings:
[0164] Figure 1This is a graph showing the anti-swelling effect of the compounds prepared in the examples of the present invention, wherein, *: comparison between the celecoxib group and the blank solvent group, p<0.05; #: comparison between the compound group of Example 20 and the blank solvent group, p<0.05; $: comparison between the compound group of Example 15 and the blank solvent group, p<0.05.
[0165] Figure 2 This is a graph showing the analgesic effect of the compound prepared in an example of the present invention on inflammatory pain, wherein, *: compared with the blank solvent group, p<0.05.
[0166] Figure 3 This is a graph showing the analgesic effect of the compound prepared in an example of the present invention on neuropathic pain, wherein, *: compared with the blank solvent group, p<0.05.
[0167] Figure 4 This is a graph showing the effect of the prepared compound provided in an example of the present invention on alleviating STZ-induced hyperglycemia, wherein, *: compared with the blank solvent group, p<0.05.
[0168] Figure 5 This is a graph showing the effect of the prepared compound provided in an embodiment of the present invention on improving glucose tolerance in diabetic mice, wherein, *: compared with the blank solvent group, p<0.05.
[0169] Figure 6 This is a diagram showing the effect of the prepared compound provided in an embodiment of the present invention on the plasma insulin level in diabetic mice, wherein, *: compared with the blank solvent group, p<0.05. Specific implementation method:
[0170] In the following examples, methods for preparing some of the compounds are described. It should be understood that the following methods and other methods known to those of ordinary skill in the art can be applied to the preparation of all compounds described in the present invention. The examples are intended to illustrate rather than limit the scope of the present invention. The H NMR spectra of the compounds were measured using a Bruker ARX-600, and the mass spectra were measured using an AgIlent 1100LC / MSD; all reagents used were analytically pure or chemically pure.
[0171] Example 1 Preparation of 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide
[0172] 1.1 Synthesis of 4-nitrobenzamide (B)
[0173] 10 g (59.9 mmol) of p-nitrobenzoic acid (A) and 45.6 g (119.8 mmol) of HATU were added to 80 mL of DMF and stirred for 0.5 h, followed by addition of 1.4 g (89.9 mmol) of ammonia water and 12.1 g (119.8 mmol) of TEA. After addition, the mixture was reacted at room temperature for 2 h. After the reaction, the reaction solution was slowly poured into 400 mL of ice water to precipitate a light brown solid. After stirring for 0.5 h, the mixture was filtered and the filter cake was washed with water and dried in an oven to obtain 7.9 g of a light brown solid with a yield of 80.2%.
[0174] 1.2 Synthesis of 4-aminobenzamide (C)
[0175] Add 13.4g (238mmol) of iron powder and 25.3g (476mmol) of ammonium chloride to 200mL of 80% methanol solution, stir at room temperature until reddish brown, then add 7.9g (47.6mmol) of intermediate B and heat to 70℃ for 3h. After the reaction is completed, filter with diatomaceous earth and rinse the filter cake with hot methanol solution, evaporate the filtrate under reduced pressure, add water to the residue, adjust the pH value to 8 with 2mol / L sodium hydroxide solution under ice water bath, stir at room temperature for 0.5h, filter with suction, wash the filter cake with water, and dry in oven to obtain 5.5g of brown solid with a yield of 85.9%.
[0176] 1.3 Synthesis of 4-{[2-(4-morpholinyl)ethyl]amino}benzamide (D)
[0177] Add 5.5 g (40.4 mmol) of intermediate C, 6.6 g (44.5 mmol) of 4-(2-chloroethyl)morpholine and 3.3 g (80.8 mmol) of NaOH to 50 mL of dry 1,4-Dioxane. After the addition, heat to 95°C and react for 6 h. After the reaction is complete, cool the reaction solution to room temperature, filter, wash the filter cake with 1,4-Dioxane, evaporate the filtrate under reduced pressure, and dry in an oven to obtain 7.0 g of brown oil with a yield of 69.5%. The crude product is directly used for the next step.
[0178] 1.4 Preparation of 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide (I)
[0179] 0.1 g (0.4 mmol) of intermediate D was added to 2 mL of dry 1,4-Dioxane, and then a solution of 0.1 g (0.4 mmol) of intermediate E in dry 1,4-Dioxane was added dropwise, and finally 0.049 g (0.48 mmol) of TEA was added. After the addition was completed, the temperature was raised to 60°C and reacted for 5 h. After the reaction was completed, the mixture was filtered while hot, and the filter cake was washed with 1,4-Dioxane and dried in an oven to obtain 0.08 g of a light white solid with a yield of 50.2%.
[0180] Example 2 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide
[0181] Using p-chloroaniline as a raw material, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 65.7%.
[0182] Example 3 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-[4-(trifluoromethoxy)phenyl]benzamide
[0183] Using 4-trifluoromethoxyaniline as a raw material, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-[4-(trifluoromethoxy)phenyl]benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 56.3%.
[0184] Example 4 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-methoxyphenyl)benzamide
[0185] Using 4-methoxyaniline as a raw material, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-methoxyphenyl)benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 63.6%.
[0186] Example 5 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-[4-(trifluoromethyl)phenyl]benzamide
[0187] Using 4-trifluoromethylaniline as a raw material, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-[4-(trifluoromethyl)phenyl]benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 46.1%.
[0188] Example 6 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-fluorophenyl)benzamide
[0189] Using 4-fluoroaniline as a raw material, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-fluorophenyl)benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 48.5%.
[0190] Example 7 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(p-tolyl)benzamide
[0191] Using 4-methylaniline as a raw material, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(p-tolyl)benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 52.6%.
[0192] Example 8 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-isopropylphenyl)benzamide
[0193] Using 4-isopropylaniline as a raw material, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-isopropylphenyl)benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 68.7%.
[0194] Example 9 N-(2-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide
[0195] Using 2-chloroaniline as a raw material, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(2-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 63.3%.
[0196] Example 10 N-(3-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide
[0197] Using 3-chloroaniline as a raw material, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(3-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 74.1%.
[0198] Example 11 N-(3-chloro-4-fluorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide
[0199] Using 3-chloro-4-fluoroaniline as a raw material, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(3-chloro-4-fluorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 61.4%.
[0200] Example 12 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-phenylbenzamide
[0201] Using aniline as a raw material, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-phenylbenzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 54.6%.
[0202] Example 13 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzenesulfonamide
[0203] Using 4-nitrobenzenesulfonyl chloride and p-chloroaniline as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzenesulfonamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 46.7%.
[0204] Example 14 N-(4-chlorobenzyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide
[0205] Using p-chlorobenzylamine as a raw material, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(4-chlorobenzyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 61.2%.
[0206] Example 15 2-(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)-N-[4-(trifluoromethoxy)phenyl]acetamide
[0207] Using 4-trifluoromethoxyaniline and 4-nitrophenylacetic acid as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 2-(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)-N-[4-(trifluoromethoxy)phenyl]acetamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 36.8%. Example 16 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-2-fluorobenzamide
[0208] Using 2-fluoro-4-nitrobenzoic acid and p-chloroaniline as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-2-fluorobenzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 46.0%.
[0209] Example 17 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-2-fluoro-N-[4-(trifluoromethoxy)phenyl]benzamide
[0210] Using 2-fluoro-4-nitrobenzoic acid and 4-trifluoromethoxyaniline as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-2-fluoro-N-[4-(trifluoromethoxy)phenyl]benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 52.4%.
[0211] Example 18 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-fluorobenzamide
[0212] Using 3-fluoro-4-nitrobenzoic acid and p-chloroaniline as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-fluorobenzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 66.7%.
[0213] Example 19 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-2-methylbenzamide
[0214] Using 2-methyl-4-nitrobenzoic acid and p-chloroaniline as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-2-methylbenzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 51.9%.
[0215] Example 20 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methylbenzamide
[0216] Using 3-methyl-4-nitrobenzoic acid and p-chloroaniline as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methylbenzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 43.4%.
[0217] Example 21 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methoxybenzamide
[0218] Using 3-methoxy-4-nitrobenzoic acid and p-chloroaniline as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methoxybenzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 56.2%.
[0219] Example 22 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-chlorobenzamide
[0220] Using 3-chloro-4-nitrobenzoic acid and p-chloroaniline as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-chlorobenzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 47.4%.
[0221] Example 23 Preparation of 2-[(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)amino]-N-cyclopropylacetamide
[0222] 23.1 Synthesis of tert-butyl (4-nitrophenyl)carbamate (G)
[0223] To a solution of 10 g (72.4 mmol) of 4-nitroaniline (F) and 0.89 g (7.28 mmol) of 4-dimethylaminopyridine in MeCN (100 mL) was added 18.9 g (86.9 mmol) of di-tert-butyl dicarbonate, and the resulting solution was stirred at 35°C for 20 h. After the reaction solution was cooled to room temperature, it was filtered and the filtrate was concentrated under reduced pressure. 240 mL of dichloromethane was added to the residue, and the mixture was washed with 5% aqueous citric acid solution (60 mL*4) and saturated brine (60 mL). The organic phase was concentrated under reduced pressure to obtain 16.55 g of a brown oil with a yield of 95.9%.
[0224] 23.2 Synthesis of tert-butyl (4-aminophenyl)carbamate (H)
[0225] Add 19.45g (363.6mmol) of iron powder and 37.61g (694.7mmol) of ammonium chloride to 200mL of a mixed solvent of methanol and water (4:1), stir at room temperature until reddish brown, add 16.6g (69.5mmol) of intermediate G, and heat to 70°C for 4h. After the reaction is complete, filter while hot with diatomaceous earth pad, wash the filter cake with hot methanol, concentrate the filtrate under reduced pressure, add 200mL of water to the residue, adjust the pH value to 8 with 2mol / L sodium hydroxide solution under ice water bath, stir at room temperature for 0.5h, filter with suction, and dry the filter cake in an oven to obtain 9.20g of brown solid with a yield of 63.5%.
[0226] 23.3 Synthesis of tert-butyl (4-{[2-(4-morpholinyl)ethyl]amino}phenyl)carbamate (I)
[0227] Add 9.2 g (44.2 mmol) of intermediate H, 7.27 g (48.6 mmol) of 4-(2-chloroethyl)morpholine and 2.65 g (66.3 mmol) of NaOH to 100 mL of dry 1,4-Dioxane. After the addition, heat to 95°C and react for 5 h. After the reaction is completed, cool the reaction solution to room temperature, filter, wash the filter cake with 1,4-Dioxane, evaporate the filtrate under reduced pressure, and dry in an oven to obtain 7.05 g of brown oil with a yield of 49.6%. The crude product is directly used for the next step.
[0228] 23.4 Synthesis of tert-butyl (4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)carbamate (J)
[0229] 7.05 g (21.9 mmol) of intermediate I and 2.67 g (26.4 mmol) of TEA were added to 80 mL of dry 1,4-Dioxane, and 5.43 g (21.9 mmol) of intermediate D were added in batches, and the temperature was raised to 60°C for reaction for 30 h. After the reaction was completed, the reaction solution was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure to obtain 17.13 g of dark brown oil, which was separated and purified by column chromatography to obtain 6.71 g of yellow oil with a yield of 64.4%.
[0230] 23.5 Synthesis of 1-(4-aminophenyl)-3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]urea (K)
[0231] 6.71 g (14.1 mmol) of intermediate J was added to 85 mL of trifluoroacetic acid in dichloromethane (4:1) and stirred at room temperature for 4 h. After the reaction was completed, the solvent was evaporated under reduced pressure, 50 ml of water was added to the residual liquid, and the pH value was adjusted to 10-12 with 2 mol / L sodium hydroxide aqueous solution, filtered, the filter cake was washed with a small amount of water, and dried in an oven to obtain 5.28 g of a light yellow solid with a yield of 99.7%.
[0232] 23.6 Preparation of 2-[(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)amino]-N-cyclopropylacetamide (I)
[0233] 0.1 g (0.3 mmol) of intermediate K, 0.054 g (0.4 mmol) of 2-chloro-N-cyclopropylacetamide, 0.074 g (0.5 mmol) of potassium carbonate and 0.014 g (0.08 mmol) of potassium iodide were added to 1.5 mL of DMF and the mixture was heated to 50° C. for 5 h. After the reaction was completed, the reaction solution was cooled to room temperature, 7.5 ml of water was added to the reaction solution, and a white solid was precipitated. After stirring at room temperature for 15 min, the mixture was filtered with suction, the filter cake was washed with water, and the filter cake was dried in an oven to obtain 0.1 g of a white solid with a yield of 79.1%.
[0234] Example 24 2-[(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)amino]-N-cyclopentylacetamide
[0235] 2-[(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)amino]-N-cyclopentylacetamide was synthesized using 2-chloro-N-cyclopentylacetamide as a raw material according to the synthesis method of 23.6 in Example 23. The yield was 63.3%.
[0236] Example 25 3-(4-chlorophenyl)-1-{4-[(2-morpholinyl-2-oxoethyl)amino]phenyl}-1-[2-(4-morpholinyl)ethyl]urea
[0237] 3-(4-chlorophenyl)-1-{4-[(2-morpholinyl-2-oxoethyl)amino]phenyl}-1-[2-(4-morpholinyl)ethyl]urea was synthesized using 2-chloro-1-morpholinethan-1-one as a raw material according to the synthesis method of 23.6 in Example 23. The yield was 54.4%.
[0238] Example 26 Preparation of N-(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)-2-(cyclopropylamino)acetamide
[0239] Add 0.4 g (1.1 mmol) of intermediate K and 0.22 g (1.6 mmol) of potassium carbonate to 10 mL of dry acetonitrile, slowly drop 0.14 g (1.2 mmol) of chloroacetyl chloride at -20 ° C, warm to room temperature and react for 2 h. After the reaction is completed by TLC monitoring, add 0.073 g (1.3 mmol) of cyclopropylamine and 0.3 g (2.2 mmol) of potassium carbonate, and continue to react for 6 h. After the reaction is completed, filter with suction, evaporate the filtrate under reduced pressure, separate and purify by column chromatography, and obtain 0.18 g of white solid with a yield of 36.3%.
[0240] Example 27 N-(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)-2-(cyclopentylamino)acetamide
[0241] Cyclopentylamine was used as a raw material to synthesize N-(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)-2-(cyclopentylamino)acetamide according to the synthesis method in Example 26. The yield was 47.2%.
[0242] Example 28 N-(4-{3-(4-chlorophenyl)-1-[2-(4-morpholino)ethyl]ureido}phenyl)-2-morpholinoacetamide
[0243] Using morpholine as a raw material, N-(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)-2-morpholinoacetamide was synthesized according to the synthesis method in Example 26. The yield was 51.3%.
[0244] Example 29 N-(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)-2-(4-methylpiperazin-1-yl)acetamide
[0245] Using 4-methylpiperazine as a raw material, N-(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)-2-(4-methylpiperazin-1-yl)acetamide was synthesized according to the synthesis method in Example 26. The yield was 43.3%.
[0246] Example 30 4-Chloro-N-(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)benzamide
[0247] Using p-chlorobenzoic acid and intermediate K as raw materials, 4-chloro-N-(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)benzamide was synthesized according to the synthesis method of 1.1 in Example 1. The yield was 59.8%.
[0248] Example 31 N-(phenyl[d][1,3]dioxanol-5-yl)-4-[3-(4-chlorophenyl)-1-(2-morpholinyl)ureido]-3-methylbenzamide
[0249] Using 3-methyl-4-nitrobenzoic acid and 3,4-methylenedioxyaniline as raw materials, the intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(phenyl[d][1,3]dioxol-5-yl)-4-[3-(4-chlorophenyl)-1-(2-morpholinyl)ureido]-3-methylbenzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 54.9%.
[0250] Example 32 4-[3-(4-chlorophenyl)-1-(2-morpholinoethyl)ureido]-3-methyl-N-[6-(trifluoromethyl)pyridin-3-yl]benzamide
[0251] Using 3-methyl-4-nitrobenzoic acid and 5-amino-2-trifluoromethylpyridine as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-[3-(4-chlorophenyl)-1-(2-morpholinoethyl)ureido]-3-methyl-N-[6-(trifluoromethyl)pyridin-3-yl]benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 36.9%.
[0252] Example 33 Preparation of N-(4-chlorophenyl)-4-{2-(cyclopropylamino)-N-[2-(4-morpholinyl)ethyl]acetamide}-3-methylbenzamide
[0253] 33.1 Synthesis of N-(4-chlorophenyl)-3-methyl-4-nitrobenzamide (M)
[0254] 20 g (110.4 mmol) of 3-methyl-4-nitrobenzoic acid (L) and 50.4 g (132.5 mmol) of HATU were added to 200 mL of DMF and stirred for 0.5 h, followed by addition of 14.8 g (110.4 mmol) of p-chloroaniline and 22.3 g (220.8 mmol) of triethylamine. After addition, the mixture was reacted at room temperature for 2 h. After the reaction, the reaction solution was slowly poured into 800 mL of ice water to precipitate a light brown solid. After stirring for 0.5 h, the mixture was filtered off with suction, the filter cake was washed with water, and oven dried to obtain 34.8 g of a light brown solid with a yield of 96.8%.
[0255] 33.2 Synthesis of 4-amino-N-(4-chlorophenyl)-3-methylbenzamide (N)
[0256] Add 33.6g (598.1mmol) of iron powder and 64.1g (1196mmol) of ammonium chloride to 500mL of 80% methanol solution, stir at room temperature until reddish brown, then add 34.7g (119.6mmol) of intermediate N, heat to 70℃ and react for 6h. After the reaction is completed, diatomaceous earth is used for hot suction filtration, the filter cake is rinsed with hot methanol solution, the filtrate is evaporated under reduced pressure, water is added to the residue, the pH value is adjusted to 8 with 2mol / L sodium hydroxide solution under ice water bath, stirred at room temperature for 0.5h, suction filtered, the filter cake is washed with water, and dried in an oven to obtain 28.8g of brown solid with a yield of 92.3%.
[0257] 33.3 Synthesis of N-(4-chlorophenyl)-3-methyl-4-{[2-(4-morpholinyl)ethyl]amino}benzamide (O)
[0258] Add 7.0 g (26.9 mmol) of intermediate N, 7.5 g (40.4 mmol) of 4-(2-chloroethyl)morpholine and 3.2 g (80.8 mmol) of NaOH to 50 mL of dry 1,4-Dioxane. After the addition, heat to 95°C and react for 6 h. After the reaction is complete, cool the reaction solution to room temperature, filter, wash the filter cake with 1,4-Dioxane, evaporate the filtrate under reduced pressure, and dry in an oven to obtain a brown oil. The crude product is directly used in the next step.
[0259] 33.4 Synthesis of 4-{2-chloro-N-[2-(4-morpholinyl)ethyl]acetamide}-N-(4-chlorophenyl)-3-methylbenzamide (P)
[0260] Dissolve 0.5 g (1.3 mmol) of intermediate O in 5 mL of acetonitrile, add 0.34 g (3.3 mmol) of potassium carbonate, and add 0.17 g (1.5 mmol) of chloroacetyl chloride dropwise in an ice bath. After the addition, continue the reaction in an ice bath for 2 h. After the reaction is complete, evaporate the solvent, add 30 mL of water to the residue for dilution, extract with dichloromethane (15 mL*2), combine the organic layers, wash the organic layers with 10 mL of 2 mol / L hydrochloric acid, and dry in an oven to obtain 0.56 g of black powder with a yield of 92.8%.
[0261] 33.5 Preparation of N-(4-chlorophenyl)-4-{2-(cyclopropylamino)-N-[2-(4-morpholinyl)ethyl]acetamide}-3-methylbenzamide (I)
[0262] Dissolve 0.55 g (1.2 mmol) of intermediate P in acetonitrile, add 0.07 g (1.2 mmol) of cyclopropylamine and 0.19 g (1.3 mmol) of potassium carbonate, and react at room temperature for 5 h. After the reaction is completed, evaporate the solvent, add 30 mL of water to the residue for dilution, extract with dichloromethane (15 mL*2), combine the organic layers, evaporate the solvent, and dry in an oven to obtain 0.43 g of black powder with a yield of 75.4%.
[0263] Example 34 N-(4-chlorophenyl)-4-{2-(cyclopentylamino)-N-[2-(4-morpholinyl)ethyl]acetamide}-3-methylbenzamide
[0264] Using cyclopentylamine as a raw material, N-(4-chlorophenyl)-4-{2-(cyclopentylamino)-N-[2-(4-morpholinyl)ethyl]acetamide}-3-methylbenzamide was synthesized according to the synthesis method of 33.5 in Example 33. The yield was 46.7%.
[0265] Example 35 N-(4-chlorophenyl)-4-{2-(4-ethylpiperazin-1-yl)-N-[2-(4-morpholinyl)ethyl]acetamide}-3-methylbenzamide
[0266] N-ethylpiperazine was used as a raw material to synthesize N-(4-chlorophenyl)-4-{2-(4-ethylpiperazine-1-yl)-N-[2-(4-morpholinyl)ethyl]acetamide}-3-methylbenzamide according to the synthesis method of 33.5 in Example 33. The yield was 36.5%.
[0267] Example 36 N-(4-chlorophenyl)-3-methyl-4-{2-morpholinyl-N-[2-(4-morpholinyl)ethyl]acetamide}benzamide
[0268] Using morpholine as a raw material, N-(4-chlorophenyl)-3-methyl-4-{2-morpholinyl-N-[2-(4-morpholinyl)ethyl]acetamide}benzamide was synthesized according to the synthesis method of 33.5 in Example 33. The yield was 56.2%.
[0269] Example 37 N-(4-chlorophenyl)-4-{2-[(4-chlorophenyl)amino]-N-[2-(4-morpholinyl)ethyl]acetamide}-3-methylbenzamide
[0270] Using p-chloroaniline as a raw material, N-(4-chlorophenyl)-4-{2-[(4-chlorophenyl)amino]-N-[2-(4-morpholinyl)ethyl]acetamide}-3-methylbenzamide was synthesized according to the synthesis method of 33.5 in Example 33. The yield was 48.9%.
[0271] Example 38 Preparation of N-(4-chlorophenyl)-4-{3-cyclopropyl-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-chlorophenyl)-3-methylbenzamide
[0272] 38.1 Synthesis of Phenyl Cyclopropyl Carbamate (Q)
[0273] 0.22 g (3.9 mmol) of cyclopropylamine and 0.24 g (2.3 mmol) of sodium carbonate were added to 40 mL of a mixed solvent of ethyl acetate, tetrahydrofuran and water (3:1:1), and 0.66 g (4.2 mmol) of phenyl chloroformate was slowly added at -20°C. After the addition, the mixture was reacted at room temperature for 2 h. After the reaction was completed, the reaction liquid was evaporated to dryness, water was added to the residue, and stirred for 0.5 h, filtered, and the filter cake was dried in a drying oven to obtain 0.59 g of a white solid with a yield of 86.3%.
[0274] 38.2 Preparation of N-(4-chlorophenyl)-4-{3-cyclopropyl-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-chlorophenyl)-3-methylbenzamide (I)
[0275] 0.3 g (0.8 mmol) of intermediate O was added to 2 mL of dry 1,4-Dioxane, and then a solution of 0.15 g (0.8 mmol) of intermediate P in dry 1,4-Dioxane was added dropwise, and finally 0.1 g (0.9 mmol) of TEA was added. After the addition was completed, the temperature was raised to 60°C and reacted for 5 h. After the reaction was completed, the mixture was filtered while hot, and the filter cake was washed with 1,4-Dioxane and dried in an oven to obtain 0.39 g of a light white solid with a yield of 67.2%.
[0276] Example 39 4-{3-[(3s,5s,7s)-adamantan-1-yl]-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-chlorophenyl)-3-methylbenzamide
[0277] Using adamantane amine as a raw material, the intermediate P was synthesized according to the synthesis method of 38.1 in Example 38, and then 4-{3-[(3s,5s,7s)-adamantan-1-yl]-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-chlorophenyl)-3-methylbenzamide was synthesized according to the synthesis method of 38.2 in Example 38. The yield was 43.2%.
[0278] Example 40 4-{3-benzyl-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-chlorophenyl)-3-methylbenzamide
[0279] Using benzylamine as a raw material, the intermediate P was synthesized according to the synthesis method of 38.1 in Example 38, and then 4-{3-benzyl-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-chlorophenyl)-3-methylbenzamide was synthesized according to the synthesis method of 38.2 in Example 38. The yield was 52.1%.
[0280] Example 41 N-(4-chlorophenyl)-3-methyl-4-{1-[2-(4-morpholinyl)ethyl]-3-phenethylureido}benzamide
[0281] Using phenylethylamine as a raw material, the intermediate P was synthesized according to the synthesis method of 38.1 in Example 38, and then N-(4-chlorophenyl)-3-methyl-4-{1-[2-(4-morpholinyl)ethyl]-3-phenylethylureido}benzamide was synthesized according to the synthesis method of 38.2 in Example 38. The yield was 48.5%.
[0282] Example 42 N-(4-chlorophenyl)-4-[3-(4-methoxyphenethyl)-1-[2-(4-morpholinyl)ethyl]ureido]-3-methylbenzamide
[0283] Using 4-methoxyphenethylamine as a raw material, the intermediate P was synthesized according to the synthesis method of 38.1 in Example 38, and then N-(4-chlorophenyl)-4-[3-(4-methoxyphenethyl)-1-[2-(4-morpholinyl)ethyl]ureido]-3-methylbenzamide was synthesized according to the synthesis method of 38.2 in Example 38. The yield was 56.3%.
[0284] Example 43 N-(4-chlorophenyl)-4-[3-(3-methoxyphenethyl)-1-[2-(4-morpholinyl)ethyl]ureido]-3-methylbenzamide
[0285] Using 3-methoxyphenethylamine as a raw material, the intermediate P was synthesized according to the synthesis method of 38.1 in Example 38, and then N-(4-chlorophenyl)-4-[3-(3-methoxyphenethyl)-1-[2-(4-morpholinyl)ethyl]ureido]-3-methylbenzamide was synthesized according to the synthesis method of 38.2 in Example 38. The yield was 47.6%.
[0286] Example 44 N-(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-(2-methoxyethyl)ureido]-3-methylbenzamide
[0287] Using 2-chloroethyl methyl ether as the raw material, the intermediate O was synthesized according to the synthesis method of 33.3 in Example 33, and then N-(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-(2-methoxyethyl)ureido]-3-methylbenzamide was synthesized according to the synthesis method of 38.2 in Example 38. The yield was 35.1%.
[0288] Example 45 Preparation of N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]ureido}-3-methylbenzamide
[0289] 45.1 Synthesis of 2-chloro-N,N-dimethylethylamine (R)
[0290] Add 0.5 g (9.9 mmol) of dimethylamine, 2.1 g (14.9 mmol) of 1-bromo-2-chloroethane and 2.1 g (14.9 mmol) of potassium carbonate to 10 mL of acetone and react at 35°C for 3 h. After the reaction is completed, filter and concentrate the filtrate under reduced pressure. Add 30 mL of 2 mol / L hydrochloric acid to the residue, extract with methyl tert-butyl ether (10 mL*2), discard the organic layer, adjust the pH value of the water layer to about 13 with 5 mol / L sodium hydroxide solution, extract with methyl tert-butyl ether (10 mL*4), collect the organic layer, and concentrate under reduced pressure to obtain 0.44 g of white solid with a yield of 36.9%.
[0291] 45.2 Synthesis of N-(4-chlorophenyl)-4-{[2-(dimethylamino)ethyl]amino}-3-methylbenzamide (X)
[0292] Add 0.3 g (1.2 mmol) of intermediate N, 0.19 g (1.8 mmol) of intermediate R and 0.14 g (3.6 mmol) of NaOH to 5 mL of dry 1,4-Dioxane. After the addition, heat to 95 °C and react for 4 h. After the reaction is completed, cool the reaction solution to room temperature, filter, wash the filter cake with 1,4-Dioxane, evaporate the filtrate under reduced pressure, and dry in an oven to obtain 0.5 g of brown oil, which is directly used in the next step.
[0293] 45.3 Preparation of N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]ureido}-3-methylbenzamide (I)
[0294] 0.5 g (1.5 mmol) of intermediate R was added to 5 mL of dry 1,4-Dioxane, and then a solution of 0.37 g (1.5 mmol) of intermediate Q in dry 1,4-Dioxane was added dropwise, and finally 0.18 g (1.8 mmol) of TEA was added. After the addition was completed, the temperature was raised to 60°C and reacted for 5 h. After the reaction was completed, the mixture was filtered while hot, and the filter cake was washed with 1,4-Dioxane and dried in an oven to obtain 0.34 g of a light white solid with a yield of 46.2%.
[0295] Example 46 N-(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-(3-morpholinopropyl)ureido]-3-methylbenzamide
[0296] Using 1-bromo-3-chloroethane and 4-(2-chloroethyl)morpholine as raw materials, the intermediate R was synthesized according to the synthesis method of 45.1 in Example 45, and then N-(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-(3-morpholinopropyl)ureido]-3-methylbenzamide was synthesized according to the synthesis method of 45.3 in Example 45. The yield was 45.6%.
[0297] Example 47 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(diethylamino)ethyl]ureido}-3-methylbenzamide
[0298] Using N,N-diethylmethylamine as a raw material, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(diethylamino)ethyl]ureido}-3-methylbenzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 45.6%.
[0299] Example 48 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(pyrrolidin-1-yl)ethyl]ureido}-3-methylbenzamide
[0300] Using tetrahydropyrrole as a raw material, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(pyrrolidin-1-yl)ethyl]ureido}-3-methylbenzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 66.6%.
[0301] Example 49 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(piperidin-1-yl)ethyl]ureido}-3-methylbenzamide
[0302] Using piperidine as a raw material, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(piperidin-1-yl)ethyl]ureido}-3-methylbenzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 57.8%.
[0303] Example 50 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-methylpiperidin-1-yl)ethyl]ureido}-3-methylbenzamide
[0304] Using 4-methylpiperidine as a raw material, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-methylpiperidin-1-yl)ethyl]ureido}-3-methylbenzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 47.3%.
[0305] Example 51 N-(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-(2-thiomorpholinoethyl)ureido]-3-methylbenzamide
[0306] Using thiomorpholine as a raw material, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46, and then N-(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-(2-thiomorpholinoethyl)ureido]-3-methylbenzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 46.3%.
[0307] Example 52 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(1-oxidothiomorpholino)ethyl]ureido}-3-methylbenzamide
[0308] Using 1-oxide-4-thiomorpholine as a raw material, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(1-oxidethiomorpholino)ethyl]ureido}-3-methylbenzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 52.9%.
[0309] Example 53 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(1,1-dioxythiomorpholino)ethyl]ureido}-3-methylbenzamide
[0310] Using 1,1-dioxide thiomorpholine as a raw material, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(1,1-dioxide thiomorpholine)ethyl]ureido}-3-methylbenzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 46.1%.
[0311] Example 54 (S)-N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(3-methylmorpholino)ethyl]ureido}-3-methylbenzamide
[0312] Using 3-(S)-3-methylmorpholine as a raw material, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46, and then (S)-N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(3-methylmorpholine)ethyl]ureido}-3-methylbenzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 77.2%.
[0313] Example 55 (R)-N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(3-methylmorpholino)ethyl]ureido}-3-methylbenzamide
[0314] Using 3-(R)-3-methylmorpholine as a raw material, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46, and then (R)-N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(3-methylmorpholine)ethyl]ureido}-3-methylbenzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 36.8%.
[0315] Example 56 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(3-oxomorpholino)ethyl]ureido}-3-methylbenzamide
[0316] Using 3-morpholinone as a raw material, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(3-oxomorpholino)ethyl]ureido}-3-methylbenzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 45.6%.
[0317] Example 57 N-(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-(2-morpholin-2-oxoethyl)ureido]-3-methylbenzamide
[0318] Using morpholine and chloroacetyl chloride as raw materials, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46, and then N-(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-(2-morpholine-2-oxoethyl)ureido]-3-methylbenzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 54.4%.
[0319] Example 58 N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(2-oxopyrrolidin-1-yl)ethyl]ureido}-3-methylbenzamide
[0320] Using 2-pyrrolidone as a raw material, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46, and then N-(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(2-oxopyrrolidin-1-yl)ethyl]ureido}-3-methylbenzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 41.0%.
[0321] Example 59 N-(4-chlorophenyl)-3-methyl-4-{3-phenethyl-1-[2-(pyrrolidin-1-yl)ethyl]ureido}benzamide
[0322] Using tetrahydropyrrolidine as a raw material, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46. Using phenethylamine as a raw material, the intermediate Q was synthesized according to the synthesis method of 38.1 in Example 38. Then, N-(4-chlorophenyl)-3-methyl-4-{3-phenethyl-1-[2-(pyrrolidin-1-yl)ethyl]ureido}benzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 38.9%.
[0323] Example 60 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methyl-N-(pyridin-2-yl)benzamide
[0324] Using 3-methyl-4-nitrobenzoic acid and 2-aminopyridine as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methyl-N-(pyridin-2-yl)benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 56.7%.
[0325] Example 61 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methyl-N-(1-methyl-1H-pyrazol-4-yl)benzamide
[0326] Using 3-methyl-4-nitrobenzoic acid and 1-methyl-4-aminopyrazole as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methyl-N-(1-methyl-1H-pyrazol-4-yl)benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 41.8%.
[0327] Example 62 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methyl-N-(thiazol-2-yl)benzamide
[0328] Using 3-methyl-4-nitrobenzoic acid and 2-aminothiazole as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methyl-N-(thiazol-2-yl)benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 56.9%.
[0329] Example 63 N-(4-acetylphenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methylbenzamide
[0330] Using 3-methyl-4-nitrobenzoic acid and 4-acetylaniline as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then N-(4-acetylphenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methylbenzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 54.9%.
[0331] Example 64 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-cyanophenyl)-3-methylbenzamide
[0332] Using 3-methyl-4-nitrobenzoic acid and 4-aminobenzonitrile as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(4-cyanophenyl)-3-methylbenzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 45.8%.
[0333] Example 65 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methyl-N-(1,3,4-thiadiazol-2-yl)benzamide
[0334] Using 3-methyl-4-nitrobenzoic acid and 2-amino-1,3,4-thiadiazole as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methyl-N-(1,3,4-thiadiazole-2-yl)benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 61.8%.
[0335] Example 66 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methyl-N-(pyrazin-2-yl)benzamide
[0336] Using 3-methyl-4-nitrobenzoic acid and 2-aminopyrazine as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methyl-N-(pyrazin-2-yl)benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 47.8%.
[0337] Example 67 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methyl-N-(pyridin-4-yl)benzamide
[0338] Using 3-methyl-4-nitrobenzoic acid and 4-aminopyridine as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methyl-N-(pyridin-4-yl)benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 36.9%.
[0339] Example 68 4-{1-[2-(1H-imidazol-1-yl)ethyl]-3-(4-chlorophenyl)ureido}-N-(4-chlorophenyl)-3-methylbenzamide
[0340] Using imidazole as a raw material, the intermediate R was synthesized according to the synthesis method of 46.1 in Example 46, and then N-(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-(2-thiomorpholinoethyl)ureido]-3-methylbenzamide was synthesized according to the synthesis method of 46.3 in Example 46. The yield was 59.9%.
[0341] Example 69 4-[3-(4-chlorophenyl)-1-(2-morpholinylethyl)ureido]-3-methyl-N-(5-methylisoxazol-3-yl)benzamide
[0342] Using 3-methyl-4-nitrobenzoic acid and 3-amino-5-methylisoxazole as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-[3-(4-chlorophenyl)-1-(2-morpholinylethyl)ureido]-3-methyl-N-(5-methylisoxazol-3-yl)benzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 47.8%.
[0343] Example 70 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(5-fluoropyridin-2-yl)-3-methylbenzamide
[0344] Using 3-methyl-4-nitrobenzoic acid and 2-amino-5-fluoropyridine as raw materials, intermediate B was synthesized according to the synthesis method of 1.1 in Example 1, and then 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-N-(5-fluoropyridin-2-yl)-3-methylbenzamide was synthesized according to the synthesis method of 1.4 in Example 1. The yield was 45.9%.
[0345] The structures and 1 H-NMR and MS data are shown in Table 1.
[0346] Table 1
[0347]
[0348]
[0349]
[0350]
[0351]
[0352]
[0353]
[0354]
[0355]
[0356]
[0357]
[0358]
[0359] The compounds of the present invention were studied for their in vitro soluble epoxide hydrolase (sEH) enzyme activity, and the results are as follows:
[0360] The compound represented by the above formula I according to the present invention (concentration 0.1 μM) was tested for in vitro sEH enzyme activity using fluorescence analysis. The reference substance t-AUCB was purchased from the market.
[0361] 12 μL of sEH enzyme (human recombinant, 0.5 mg / mL, Cayman Chemical) was diluted with 588 μL of buffer (25 mM bis-Tris, pH 7.0). The fluorescent substrate was a DMSO solution (10 μM, Cayman Chemical) of PHOME [(3-phenyl-oxacyclopropyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester]. The table prepared in the above example was used as the test compound and dissolved in 100% DMSO at a concentration of 4 μM. 185 μL of buffer (25 mM bis-Tris, pH 7.0), 5 μL of compound solution and 5 μL of diluted sEH enzyme were added to each well of a 96-well plate, and finally 5 μL of substrate solution was added to start the reaction as the experimental group, and then the signal was measured by a microplate reader after incubation at 37° C. for 15 min (excitation wavelength 330 nm, emission wavelength 465 nm). At the same time, the background group and the full live group were set up. No compound and enzyme were added to the background group (replaced with DMSO and buffer, respectively), and no compound was added to the full live group (replaced with DMSO), and then incubated and measured in the above manner. The inhibition rate was calculated using the data of the full live group (F0) and the compound group (F1) after deducting the background group fluorescence signal:
[0362] Inhibition rate (%) = (F0-F1) / (F0)×100.
[0363] The results of the in vitro sEH enzyme activity test of the example compounds are shown in Table 2.
[0364] Table 2
[0365]
[0366]
[0367] According to the above, some compounds of the present invention were further subjected to in vitro soluble epoxide hydrolase (sEH) IC 50 The test results are as follows
[0368] The compound represented by the above formula I according to the present invention was tested for in vitro sEH enzyme activity by fluorescence analysis. The reference substance t-AUCB was purchased from the market.
[0369] 12 μL of sEH enzyme (human recombinant, 0.5 mg / mL, Cayman Chemical) was diluted with 588 μL of buffer (25 mM bis-Tris, pH 7.0). The fluorescent substrate was a DMSO solution of PHOME [(3-phenyl-oxacyclopropyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester] (10 μM, Cayman Chemical). The table compound prepared in the above example was used as the test compound, which was dissolved in 100% DMSO to a concentration of 4 μM, and then diluted with 100% DMSO to 2 μM, 1 μM, 0.5 μM, 0.25 μM, 0.04 μM, 0.02 μM, 0.004 μM and 0.0004 μM solutions of different concentrations. The inhibition rate of the compound at different concentrations was determined according to the inhibition rate determination method, and the IC was calculated. 50 .
[0370] sEH enzyme IC of some examples 50 The activity data are shown in Table 3.
[0371] Table 3
[0372]
[0373]
[0374] The above in vitro sEH enzyme activity test results show that the compounds of general formula I to be protected by the present invention have good sEH inhibitory activity, and some of the compounds are equivalent to or better than the positive control drug t-AUCB.
[0375] Example 71 Anti-inflammatory Effect Determination
[0376] Male KM mice (6-8 weeks old) were subcutaneously injected with 50 μL of 1% carrageenan saline solution to establish an inflammatory swelling model. The mice were intraperitoneally injected with the compound solution prepared in Examples 15 and 20, celecoxib solution or blank solvent at a dose of 100 mg / kg 1 hour before the injection of carrageenan. The thickness of the mouse paw was measured with a vernier caliper. The initial paw thickness of the mouse before modeling was 100%, and the change in the paw thickness of the mouse after the injection of carrageenan was measured (see Figure 1 ). The results showed that the compounds of Example 15 and Example 20 could significantly inhibit carrageenan-induced mouse foot swelling, and the effect was comparable to that of celecoxib.
[0377] The compounds of Examples 15 and 20 and celecoxib were dissolved in DMSO to prepare solutions with a concentration of about 25 mg / mL; the blank solvent was DMSO. The injection volume was about 0.1 mL.
[0378] Example 72 Analgesic Effect Determination
[0379] Inflammatory pain
[0380] Male SD rats (200-250 g) were subcutaneously injected with 50 μL of 1% carrageenan saline solution to establish an inflammatory pain model. The rats were intraperitoneally injected with the compound solutions prepared in Examples 15, 41 and 48, celecoxib solution or blank solvent 1 hour before the injection of carrageenan. The mechanical stimulation paw withdrawal threshold (MWT) of the rats was measured using an electronic Von Frey analgesic instrument. The initial MWT before modeling was 100%, and the changes in the MWT of the rats after the injection of carrageenan were measured (see Figure 2 The results showed that the compounds could significantly improve the MWT of rats and relieve pain, and the analgesic effects of the compounds of Example 15, Example 41 and Example 48 were better than those of celecoxib.
[0381] The compound of Example 15 and celecoxib were dissolved in DMSO to prepare a solution with a concentration of about 40 mg / mL, and the compounds of Examples 41 and 48 were dissolved in DMSO to prepare a solution with a concentration of about 20 mg / mL; the blank solvent was DMSO. The injection volume was about 0.55 mL. The dosages were 100 mg / kg (Example 15, celecoxib) and 50 mg / kg (Examples 41 and 48), respectively.
[0382] Neuropathic pain
[0383] Male SD rats (260-300g) were anesthetized by intraperitoneal injection of chloral hydrate, and the muscles were bluntly separated to expose the sciatic nerve. Four ligatures were made at the proximal end of the trifurcated branch with 4-0 catgut, and the muscles and skin were sutured and disinfected to establish a rat model of chronic sciatic nerve compression injury (CCI). The mechanical stimulation paw withdrawal threshold (MWT) of rats was measured using an electronic Von Frey analgesic meter, and pharmacodynamic evaluation was performed when the MWT dropped to less than 70% before surgery. One week after modeling, the rats were intraperitoneally injected with the compound solution prepared in Examples 20 and 48, gabapentin solution or blank solvent. The changes in the MWT of rats at different times after administration were measured (see Figure 3 ). The results showed that the compounds could significantly improve the MWT of rats and relieve neuropathic pain. The analgesic effect of the compound of Example 20 was comparable to that of gabapentin, and the analgesic effect of the compound of Example 48 was superior to that of gabapentin. The compound of Example 20 and gabapentin were dissolved in DMSO to prepare a solution with a concentration of about 40 mg / mL, and the compound of Example 48 was dissolved in DMSO to prepare a solution with a concentration of about 20 mg / mL; the blank solvent was DMSO. The injection volume was about 0.55 mL. The dosages were 100 mg / kg (Example 20, gabapentin) and 50 mg / kg (Example 48), respectively.
[0384] Example 73 Hypoglycemic Effect Determination
[0385] Male BALB / c mice (6-8 weeks old) were intraperitoneally injected with streptozotocin (STZ, once a day) at 50 mg / kg for 5 consecutive days to establish a diabetes model. Another group of mice were injected with saline at the above injection dose for 5 consecutive days as a normal control group. After the modeling began, the mice were given an aqueous solution of the compound prepared in Example 20 (0.025 mg / mL, prepared with 2.5% HP-β-CD solution) or blank solvent by drinking water, and the dosage was about 10 mg / kg. The fasting blood glucose of the mice was measured every week, and a glucose tolerance test and plasma insulin content were measured in the fourth week of the modeling (see Figure 4-6 ). The results showed that the compound of Example 20 could significantly alleviate STZ-induced hyperglycemia and decreased plasma insulin content, and improve glucose tolerance in mice.
Claims
1. A benzamide derivative, characterized in that: Benzamide derivatives are N -(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido]benzamide 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}- N -[4-(Trifluoromethoxy)phenyl]benzamide 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}- N -(4-methoxyphenyl)benzamide 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}- N -[4-(Trifluoromethyl)phenyl]benzamide 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}- N -(4-Fluorophenyl)benzamide 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}- N -(p-Tolyl)benzamide 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}- N -(4-isopropylphenyl)benzamide N -(2-Chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide N -(3-Chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide N -(3-chloro-4-fluorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}- N -Phenylbenzamide N -(4-Chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzenesulfonamide N -(4-Chlorobenzyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}benzamide 2-(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)- N -[4-(Trifluoromethoxy)phenyl]acetamide N -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-2-fluorobenzamide 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-2-fluoro- N -[4-(Trifluoromethoxy)phenyl]benzamide N -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-fluorobenzamide N -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-2-methylbenzamide N -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methylbenzamide N -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methoxybenzamide N -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-chlorobenzamide 2-[(4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}phenyl)amino]- N -Cyclopropylacetamide 4-{3-Benzyl-1-[2-(4-morpholinyl)ethyl]ureido}- N -(4-Chlorophenyl)-3-methylbenzamide N -(4-Chlorophenyl)-3-methyl-4-{1-[2-(4-morpholinyl)ethyl]-3-phenylethylureido}benzamide N -(4-chlorophenyl)-4-{3-(4-methoxyphenethyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methylbenzamide N -(4-Chlorophenyl)-4-{3-(3-methoxyphenethyl)-1-[2-(4-morpholinyl)ethyl]ureido}-3-methylbenzamide N -(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-(2-methoxyethyl)ureido]-3-methylbenzamide N Preparation of -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]ureido}-3-methylbenzamide N -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(diethylamino)ethyl]ureido}-3-methylbenzamide N -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(pyrrolidin-1-yl)ethyl]ureido}-3-methylbenzamide N -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(piperidin-1-yl)ethyl]ureido}-3-methylbenzamide N -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(4-methylpiperidin-1-yl)ethyl]ureido}-3-methylbenzamide N -(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-(2-thiomorpholinoethyl)ureido]-3-methylbenzamide N -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(1-oxidothiomorpholino)ethyl]ureido}-3-methylbenzamide N -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(1,1-dioxythiomorpholino)ethyl]ureido}-3-methylbenzamide N -(4-chlorophenyl)-4-{3-(4-chlorophenyl)-1-[2-(3-oxomorpholino)ethyl]ureido}-3-methylbenzamide 4-{3-(4-chlorophenyl)-1-[2-(4-morpholinyl)ethyl]ureido}- N -(5-fluoropyridin-2-yl)-3-methylbenzamide.
2. The benzamide derivative according to claim 1, characterized in that: The salt formed by the compound of claim 1 and an acid, wherein the acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, trifluoroacetic acid or aspartic acid.
3. A pharmaceutical composition, characterized in that: The composition contains one or more of the compounds according to claim 1 or 2 and pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
4. Use of the compound according to claim 1 or 2 and its pharmaceutically acceptable salt or the composition according to claim 3 in the preparation of a drug for treating and / or preventing sEH-mediated diseases.
5. The use according to claim 4, characterized in that: The diseases include inflammatory diseases, cardiovascular and cerebrovascular diseases, diabetes, fibrotic diseases, neurological and psychiatric diseases, pain or ulcerative diseases.
